In 2017, Indivior PLC received the U.S. Food and Drug Administration (FDA) approval for its new SUBLOCADE (buprenorphine extended- release) injection for subcutaneous use. SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder.

Traffic Management System Market

Virtual Data Room

Innovation Management

innovation management

Microhydro-Electric Systems Market

Global Open Source Services Market

Drug for Abuse Testing Devices Market Register a Hugh Growth In Healthcare Industry by 2026